Evidence-based approach to challenging issues in the management of invasive aspergillosis

References

• Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52–59
   PubMed Web of Science ®Google Scholar
• Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients: report of 9 cases and review of the literature. Medicine 1996; 75: 142–156
   PubMed Web of Science ®Google Scholar
• Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44–69
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909–917
   PubMed Web of Science ®Google Scholar
• Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive Aspergillus. Cancer 2006; 107: 2888–2897
   PubMed Web of Science ®Google Scholar
• Mattner F, Chaberny IF, Weibrodt H, et al. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 2005; 48: 51–55
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning D, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Husain S, Paterson DL, Studer SM, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 12: 2765–2773
   Google Scholar
• Sole A, Morant P, Salavert M, et al. Aspergillus in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11: 359–365
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957–1968
   PubMed Web of Science ®Google Scholar
• Roilides E, Dignani MC, Anaissie EJ, et al. The role of immunoreconstitution in the management of refractory opportunistic fungal infections. Med Mycol 1998; 36: 12–25
   PubMed Web of Science ®Google Scholar
• Grazziutti ML, Rex JH, Cowart RE, et al. Aspergillus fumigatus conidia induce a Th1-type cytokine response. J Infect Dis 1997; 176: 1579–1583
   PubMed Web of Science ®Google Scholar
• Roilides E, Dimitriadou-georgiadou A, Sein T, et al. Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus. Infect Immun 1998; 66: 5999–6003
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 2001; 16: 60–66
   PubMedGoogle Scholar
• Hebart H, Bollinger C, Fisch P, et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individual and patients with hematologic malignancies. Blood 2003; 100: 4521–4528
   Web of Science ®Google Scholar
• Zelante T, De Luca A, Bonifazi P, et al. IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 2007; 37: 2695–2706
   PubMed Web of Science ®Google Scholar
• Singh N, Lortholary O, Alexander BD, et al. An ‘immune reconstitution syndrome’-like entity associated with Cryptococcus neoformans infections in organ transplant recipients. Clin Infect Dis 2005; 40: 1756–1761
   PubMed Web of Science ®Google Scholar
• Cheng VCC, Yuen K-Y, Chan W-M, et al. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30: 882–892
   PubMed Web of Science ®Google Scholar
• Miceli M, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110: 112–120
   PubMed Web of Science ®Google Scholar
• Singh N, Perfect JR. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 2007; 7: 395–401
   PubMed Web of Science ®Google Scholar
• Summers SA, Dorling A, Boyle JJ, et al. Cure of disseminated cryptococcal infection in a renal allograft recipient after the addition of γ-interferon to antifungal therapy. Am J Transplant 2005; 5: 2067–2069
   PubMed Web of Science ®Google Scholar
• Lanternier F, Chandesris M, Poirée S, et al. Cellulitis revealing a cryptococcosis-related immune reconstitution inflammatory syndrome in a renal allograft recipient. Am J Transplant 2007; 12: 2826–2828
   Web of Science ®Google Scholar
• Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Groll A, Renz S, Gerein V. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF). Mycoses 1992; 35: 67–75
   PubMed Web of Science ®Google Scholar
• Todeschini G, Murari C, Bonesi R, et al. Invasive aspergillosis in neutropenic patients: rapid neutrophil recovery is a risk factor for severe pulmonary complications. Eur J Clin Invest 1999; 29: 453–457
   PubMed Web of Science ®Google Scholar
• Woods G, Miceli M, Grazziutti M, et al. Serum Apergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 2007; 110: 830–834
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201–241
   PubMed Web of Science ®Google Scholar
• Saad AH, DePestel DD, Carver PL. Factors influencing the magnitide and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730–1744
   PubMed Web of Science ®Google Scholar
• Isoherranen N, Kunze KL, Allen K, et al. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004; 32: 1121–1131
   PubMed Web of Science ®Google Scholar
• Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation; a report of two cases. Transplant Proc 2004; 36: 2708–2709
   PubMed Web of Science ®Google Scholar
• Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 552–559
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Martinho M, et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 2007; 6: 825–834
   Google Scholar
• Verweij P, Meis J. Microbiological diagnosis of invasive fungal infectious transplant recipients. Transplant Infect Dis 2000; 2: 80–87
   PubMedGoogle Scholar
• Sable CA, Nguyen BY, Chodakewitz JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transplant Infect Dis 2002; 4: 25–30
   PubMedGoogle Scholar
• Sanz-Rodriguez C, Lopez-Duarte M, Jurado M, et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplant 2004; 34: 13–20
   PubMed Web of Science ®Google Scholar
• Anttila VJ, Piilonen A, Valtonen M. Co-administration of caspofungin and cyclosporine to a kidney transplant patient with pulmonary Aspergillus infection. Scand J Infect Dis 2003; 35: 893–894
   PubMedGoogle Scholar
• Saner F, Gensicke J, Rath P, et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34: 328–332
   PubMed Web of Science ®Google Scholar
• Vazquez J. Anidulafungin: a new echinocandin with a novel profile. Clin Ther 2005; 27: 657–673
   PubMed Web of Science ®Google Scholar
• Dowell J, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47: 461–470
   PubMed Web of Science ®Google Scholar
• Dowell, J, Schranz, J, Baruch, A, , et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005; 1373–1382.
   PubMed Web of Science ®Google Scholar
• Jospeh J, Jain R, Danziger L. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007; 27: 53–67
   PubMed Web of Science ®Google Scholar
• Herbert M, Blough D, Townsend R, et al. Concomitant cyclosporine and micafungin pharmacokinetcs in healthy volunteers. J Clin Pharmacol 2005; 45: 1018–1024
   PubMed Web of Science ®Google Scholar
• Cahanrasekar P, Sobel J. Reviews of anti-infective agents. Micafungin: a new echinocandin. Clin Infect Dis 2006; 45: 883–893
   Google Scholar
• Odom A, Muir S, Lim E, et al. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J 1997; 16: 2576–2589
   PubMed Web of Science ®Google Scholar
• Cruz MC, Goldstein AL, Blankenship JR, et al. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO Journal 2002; 21: 546–559
   PubMed Web of Science ®Google Scholar
• Steinbach W, Cramer RA, Perfect BZ, et al. Calcineurin controls growth, morphology, and pathogenicity in Aspergillus fumigatus. Eukaryotic Cell 2006; 5: 1091–1103
   PubMed Web of Science ®Google Scholar
• Steinbach W, Cramer RA, Perfect BZ, et al. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus. Antimicrob Agents Chemotherap 2007; 81: 2979–2981
   Google Scholar
• Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive apergillosis. Clin Infect Dis 2004; 39: 797–802
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DPR, Lewis RE, Lionakis MS, et al. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity. Diag Microbiol Infect Dis 2003; 47: 415–419
   PubMed Web of Science ®Google Scholar
• Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B standard dose in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients: randomized pilot study (combistrat trial). Cancer 2006; 110: 2740–2746
   Web of Science ®Google Scholar
• Singh N, Limaye A, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter observational trial. Transplantation 2006; 81: 320–326
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM, Cacciarelli TV, et al. Antifungal management practices in liver transplant recipients. Am J Transplant 2008; 8: 426–431
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. CID 2008; 46: 327–360
   PubMed Web of Science ®Google Scholar
• Muñoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections; should a combination of antifungal drugs be used?. Curr Opin Immunol 2006; 19: 365–370
   Google Scholar